HSP Complete 15 (15 Billions)

Human Strain Probiotics (HSP) Complete 15 provides 7 clinically studied human strains at a potency of 15 billion colony forming units (CFU) per vegetarian capsule, with a balance of probiotics to target the small and large intestinal flora. Unlike enteric-coated or delayed-release products, the capsules are designed to target the duodenum and exert maximal gut-brain support when taken with food. It is approved by Health Canada and obtained the Natural Product Number (80112170).
Ingredients: Lactobacillus acidophilus (DDS-1) 5 billion CFU, Bifidobacterium animalis subsp. lactis (BL-04) 2 billion CFU, Lactococcus lactis (LL-23) 2 billion CFU, Lactobacillus rhamnosus (GG) 2 billion CFU, Bifidobacterium animalis subsp. lactis (HN019) 1.8 billion CFU, Lactobacillus acidophilus (LA-14) 1.2 billion CFU, Bifidobacterium bifidum (BB-06) 1 billion CFU.
Other Ingredients: Microcrystalline cellulose, Oryza sativa (rice) hull powder, trehalose, hypromellose, water.

Digestive Benefits: HSP Complete 15 is formulated with 2 billion CFU of Lactobacillus acidophilus DDS-1, a strain clinically shown to reduce gastrointestinal discomfort in travel and lactose intolerance. Additionally, this strain has demonstrated an ability to regulate bowel habits and stool consistency. In a double-blind placebo-controlled RCT, Bifidobacterium animalis subsp. lactis HN019 was shown to significantly increase frequency of bowel movements in patients struggling with less than 3 movements per week.
Immune System Benefits: In another trial with adults 70 years of age and older, HN019 was shown to increase helper T lymphocyte and natural kill cell activity in patients with low immune response.
In a clinical trial comparing the effectiveness of various probiotic strains on immune responses, groups administered Lactobacillus acidophilus LA-14 or Bifidobacterium animalis subsp. lactis BL-04 were shown to significantly increase serum IgG, compared to controls. In a randomized, double-blind placebo-controlled trial, Bifidobacterium animalis subsp. lactis BL-04 was shown to reduce the incidence of respiratory tract infection and viral shedding after being administered during a rhinovirus infection and supplementing with the probiotic strain for an additional 28 days.
In another double-blind placebo-controlled trial with 465 healthy adults, Bifidobacterium animalis subsp. lactis BL-04 (at a dose of 2 billion CFU) was shown to be more effective than placebo and a multi-strain probiotic (19% reduction vs. 27% reduction) in reducing the incidence of respiratory tract infection and improving immunity.
Metabolic Benefits: Chronic medical conditions like obesity and hypertension are modifiable cardiometabolic risk factors highly predictive of hospitalization. HSP probiotics have been formulated to address the inflammatory biomarkers, hypercholesterolemia, and elevated BMI typically seen in people with reduced immune function. In a randomized double-blind placebo-controlled trial with 32 overweight and obese women, HSP strains were shown to be significantly correlated with BMI, weight, fat mass, lean mass, conicity index, protein intake, monounsaturated fat intake, glycated hemoglobin, TNF-α, and IL6/IL10. The bifidobacteria HSP strains have also demonstrated specific cholesterol absorption properties, leading to decreases in serum total cholesterol and LDL-C.
Heavily Clinically Researched Strains: Lactobacillus rhamnosus GG is among the world's most heavily studied probiotic strains, and it is an integral part of the HSP Complete formula. With a dose of 2 billion CFU, the digestive, cognitive, and immune health are covered.
Supplementation of rhamnosus GG has been clinically shown to reduce the risk of upper respiratory tract infections, rhinovirus-induced symptoms, acute otitis media, and antibiotic use in populations dealing with viral respiratory infections.
In trials with hospitalized children in both India and Poland, supplementation with rhamnosus GG significantly reduced hospital stay, along with frequency & duration of diarrhea and ensuing IV therapy requirements. In rotavirus-associated diarrhea, rhamnosus GG supplementation reduced the duration of symptoms, improved gastrointestinal function, and increased IgG.
In patients with ulcerative colitis, rhamnosus GG was shown to be as effective as mesalazine with respect to relapse rate after 6 months of supplementation. The probiotic had a better adverse event profile, and was more effective than the drug in promoting "relapse-free time".
In a randomized placebo-controlled trial tracking 6-month-old infants to 13 years of age, use of Lactobacillus rhamnosus GG resulted in significant risk reduction of ADHD and Asperger's syndrome.
In two separate clinical trials, rhamnosus GG supplementation starting in the second trimester of pregnancy reduced the severity of maternal allergic disease. During pregnancy and breastfeeding up to the first 2 years of an infant's life, a study on maternal rhamnosus GG supplementation demonstrated a reduced risk of atopic dermatitis. Extending the benefits to immune and skin health even further, rhamnosus GG supplementation has also been shown to reduce the risk of a child developing atopic dermatitis (eczema), compared to placebo, when taken consistently in the first 7 years of life.

Recommended Usage: Assist in overall gut digestive health.
Improve intestinal transit time.
Enhance immune reactions.
Increase absorption of vitamins and nutrients.
Boost metabolism.
Stabilize gut flora during antibiotic therapy.

Recommended Dose: Adults (18 and older): Take 1 capsule once daily or as directed by a healthcare practitioner. Take at least 2-3 hours before or after antibiotics.

Shelf stable. Store in room temperature.

Supplements & Adjuvant Therapy

A07FA51 - lactic acid producing organisms, combinations ; Belongs to the class of antidiarrheal microorganisms. Used in the treatment of diarrhea.